Invex Therapeutics (ASX:IXC) Days Payable: 0.00 (As of Dec. 2025)


ASX:IXC Invex Therapeutics Ltd ASX:IXC
37 GF Score
Price A$0.11
! 1 Warning Sign
View Full Analysis

What is Invex Therapeutics Days Payable?

Invex Therapeutics ASX:IXC 37 Days Payable is 0.00 as of Dec. 2025. GuruFocus rates ASX:IXC with a GF Score™ of 37/100. The stock has 1 warning sign investors should review. Among 708 Biotechnology companies, Invex Therapeutics ranks worse than 141242.8% on this metric.

Invex Therapeutics's average Accounts Payable for the six months ended in Dec. 2025 was A$0.17 Mil. Invex Therapeutics's Cost of Goods Sold for the six months ended in Dec. 2025 was A$0.00 Mil.

The historical rank and industry rank for Invex Therapeutics's Days Payable or its related term are showing as below:

ASX:IXC's Days Payable is not ranked *
in the Biotechnology industry.
Industry Median: 113.56
* Ranked among companies with meaningful Days Payable only.

Invex Therapeutics's Days Payable stayed the same from Dec. 2024 (0.00) to Dec. 2025 (0.00).

Invex Therapeutics Days Payable Historical Data

* Premium members only.

The historical data trend for Invex Therapeutics's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Invex Therapeutics Days Payable Chart

Invex Therapeutics Annual Data
Trend Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Days Payable
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Invex Therapeutics Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Days Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ASX:IXC vs VRTX, REGN, ALNY: Days Payable Comparison

For the Biotechnology subindustry, Invex Therapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Invex Therapeutics Days Payable vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Invex Therapeutics's Days Payable distribution charts can be found below:

* The bar in red indicates where Invex Therapeutics's Days Payable falls into.


ASX:IXC
37GF Score
Invex Therapeutics Ltd ASX:IXC
Days Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Invex Therapeutics Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Invex Therapeutics's Days Payable for the fiscal year that ended in Jun. 2025 is calculated as

Days Payable (A: Jun. 2025 )
=Average Accounts Payable /Cost of Goods Sold*Days in Period
=( (Accounts Payable (A: Jun. 2024 ) + Accounts Payable (A: Jun. 2025 )) / count ) / Cost of Goods Sold (A: Jun. 2025 )*Days in Period
=( (0.006 + 0.169) / 2 ) / 0*365
=0.0875 / 0*365
=N/A

Invex Therapeutics's Days Payable for the quarter that ended in Dec. 2025 is calculated as:

Days Payable (Q: Dec. 2025 )
=Average Accounts Payable / Cost of Goods Sold*Days in Period
=( (Accounts Payable (Q: Jun. 2025 ) + Accounts Payable (Q: Dec. 2025 )) / count ) / Cost of Goods Sold (Q: Dec. 2025 )*Days in Period
=( (0.169 + 0.176) / 2 ) / 0*365 / 2
=0.1725 / 0*365 / 2
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Days Payable →
What does a Days Payable of 0.00 mean?
Invex Therapeutics (ASX:IXC) has a Days Payable of 0.00 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Invex Therapeutics and its competitors. According to the industry distribution chart, Invex Therapeutics ranks #999999 out of 708 companies in the Biotechnology industry.
Is Invex Therapeutics' Days Payable too high?
Invex Therapeutics' current Days Payable is 0.00. Based on the distribution chart, Invex Therapeutics ranks #999999 out of 708 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Invex Therapeutics has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Invex Therapeutics' Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Invex Therapeutics ranks #999999 out of 708 companies for Days Payable. This places Invex Therapeutics in the lower half of its industry. The industry median Days Payable is 113.56. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.56, based on 708 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Invex Therapeutics and its competitors. For the Biotechnology industry, the median Days Payable is 113.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Invex Therapeutics's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Invex Therapeutics stock overvalued right now?
Invex Therapeutics (ASX:IXC) has a current Days Payable of 0.00. The current Days Payable is 0.00. Invex Therapeutics' overall GF Score™ is 37/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Invex Therapeutics (ASX:IXC), the current Days Payable is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Invex Therapeutics Business Description

Address c/- Automic Group, Level 5, 191 St Georges Terrace, Perth, WA, AUS, 6000
Invex Therapeutics Ltd is a biopharmaceutical company, focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised ICP including TBI, stroke and hydrocephalus. In addition, the Group has generated early-stage data on the use of Exenatide in the treatment of glaucoma, through the lowering of intraocular pressure in the eye. Geographically, it operates only in Australia.
37GF Score

Get the complete analysis for ASX:IXC

Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.11
Price